Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NurExone Biologic ( (TSE:NRX) ) has provided an update.
NurExone Biologic’s U.S. subsidiary Exo-Top has signed a non-binding letter of intent with Florida-based BioXtek to explore a strategic partnership for Good Manufacturing Practice-compliant production and commercialization of bone marrow–derived mesenchymal stem cell exosomes. The contemplated deal would pair NurExone’s proprietary Master Cell Bank and exosome know-how with BioXtek’s U.S. manufacturing footprint to expand clinical supply and production capacity in the U.S. and abroad.
The partners plan to collaborate on consistent GMP manufacturing processes, joint supply strategies for wound care, pain management and orthopedic uses, and potential support for NurExone’s planned U.S. clinical trials of its lead candidate ExoPTEN. If finalized, the arrangement could accelerate NurExone’s path to market in both therapeutic and rapidly growing regenerative aesthetics segments, while positioning the parties for a stronger competitive role in the emerging exosome market.
More about NurExone Biologic
NurExone Biologic is a biotechnology company focused on regenerative therapies based on mesenchymal stem cell exosomes. Through its U.S. subsidiary Exo-Top, the company is developing exosome-based platforms and nanodrugs targeting indications such as acute spinal cord injury and optic nerve damage, with an eye on both therapeutic and regenerative aesthetics markets.
Average Trading Volume: 25,521
Technical Sentiment Signal: Hold
Current Market Cap: C$48.31M
See more insights into NRX stock on TipRanks’ Stock Analysis page.